EUCTR2016-002980-33-ES进行中（未招募）1 期
A Phase 3, Randomized, Open-Label, Multicenter StudyComparing the Efficacy and Safety of the Bruton’s TyrosineKinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjectswith Waldenström’s Macroglobulinemia (WM)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 167
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Clinical and definitive histologic diagnosis of WM
- •2. Meeting at least one criterion for treatment according to consensus panel criteria from the Seventh International Workshop on Waldenström’s macroglobulinemia (Dimopoulos et al 2014)
- •3. For subjects who have received no prior therapy for WM, they must be considered inappropriate candidates for treatment with a standard chemoimmunotherapy regimen
- •4. Measurable disease, as defined by serum IgM level >0.5 g/dL
- •5. Age = 18 years old
- •6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •7. Adequate bone marrow function defined as:
- •- Neutrophils = 0.75 x 10 power 9/L independent of growth factor support within 7 days of study entry
- •- Platelets = 50 x 10 power 9/L, independent of growth factor support or transfusion within 7 days of study entry
- •8. Creatinine clearance of = 30 ml/min (as estimated by the Cockcroft-Gault equation or estimated glomerular filtration rate [eGFR] from the Modification of Diet in Renal Disease [MDRD])
- •13. Subjects may be enrolled who relapse after autologous stem cell transplant if they are at least 3 months after transplant, and after allogeneic transplant if they are at least 6 months posttransplant. To be eligible after either type of transplant, subjects should have no active
- •related infections or in the case of allogeneic transplant relapse, no active acute graft versus host disease (GvHD) of any grade, and no chronic GvHD other than mild skin, oral, or ocular GvHD not requiring systemic immunosuppression.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 67
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1. Prior exposure to a BTK inhibitor.
- •2. Evidence of disease transformation at the time of study entry.
- •3. Corticosteroids given with anti-neoplastic intent within 7 days, or chemotherapy, targeted therapy, or radiation therapy within 3 weeks, or antibody-based therapy within 4 weeks of the start of study drug.
- •4. Major surgery within 4 weeks of study treatment.
- •5. Toxicity of = Grade 2 from prior anticancer therapy (except for alopecia, absolute neutrophil count [ANC] and platelets). For ANC and platelets, please follow inclusion criteria #7 [neutrophils] and [platelets]).
- •6. History of other active malignancies within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally (surgery or other modality) with curative intent.
- •7. Currently active, clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease as defined by the New York Heart Association (NYHA) Functional Classification, or history of myocardial infarction within 6 months of screening.
- •8. QTcF prolongation (defined as a QTcF > 450 msec)
- •9. Active, clinically significant Electrocardiogram (ECG) abnormalities including second degree atrioventricular (AV) block Type II, or third degree AV block.
- •10. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
- •11. Uncontrolled active systemic infection or recent infection requiring parenteral anti-microbial therapy that was completed =14 days before the first dose of study drug.
- •12. Known human immunodeficiency virus (HIV), or active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (eg, hepatitis C virus [HCV] ribonucleic acid [RNA] detected).
研究者
相似试验
进行中（未招募）
1 期
A study to compare the experimental medicine T-Guard to Ruxolitinib for treating acute Graft-versus-Host Disease that does not sufficiently improvewith the standard steroid treatmentEUCTR2021-000343-53-ITXenikos B.V.246
进行中（未招募）
1 期
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the medications BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macroglobulinemia (WM)Subjects with Waldenström’s Macroglobulinemia (WM) who require therapy according to the consensus panel criteria from the 7th International Workshop on Waldenström’s MacroglobulinemiaMedDRA version: 20.0Level: PTClassification code 10047801Term: Waldenstrom's macroglobulinaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002980-33-CZBeiGene USA, Inc.210
进行中（未招募）
1 期
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the medications BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macroglobulinemia (WM)Subjects with Waldenström’s Macroglobulinemia (WM) who require therapy according to the consensus panel criteria from the 7th International Workshop on Waldenström’s MacroglobulinemiaMedDRA version: 21.0Level: PTClassification code 10047801Term: Waldenstrom's macroglobulinaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002980-33-GRBeiGene Ltd. c/o BeiGene USA Inc.210
进行中（未招募）
1 期
A study to compare the experimental medicine T-Guard to Ruxolitinib for treating acute Graft-versus-Host Disease that does not sufficiently improve with the standard steroid treatmentEUCTR2021-000343-53-NLXenikos B.V.246
进行中（未招募）
1 期
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the medications BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macroglobulinemia (WM)Subjects with Waldenström’s Macroglobulinemia (WM) who require therapy according to the consensus panel criteria from the 7th International Workshop on Waldenström’s MacroglobulinemiaMedDRA version: 21.0Level: PTClassification code 10047801Term: Waldenstrom's macroglobulinaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002980-33-GBBeiGene Ltd. c/o BeiGene USA Inc.210